<DOC>
	<DOCNO>NCT00075556</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy , capecitabine , use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy surgery may shrink tumor remove . PURPOSE : This phase II trial study well neoadjuvant radiation therapy capecitabine work treat patient undergo surgery stage III stage IV colorectal adenocarcinoma .</brief_summary>
	<brief_title>Neoadjuvant Radiation Therapy Capecitabine Treating Patients With Stage III Stage IV Colorectal Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective tumor response rate patient stage III IV colorectal adenocarcinoma treat neoadjuvant radiotherapy capecitabine . Secondary - Determine tolerance profile regimen patient . - Determine rate preservation functional integrity anal sphincter patient treat regimen . - Compare conversion rate effect mutilate surgery v surgery sphincter preservation patient treat regimen . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily undergo concurrent radiotherapy 5 day week week 1-5 . Patients undergo surgery week 6 . Patients follow every 4 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 48 patient accrue study within 10 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal adenocarcinoma Clinical stage T3 , T4 , N+ Measurable disease Awaiting surgery likely benefit neoadjuvant radiotherapy PATIENT CHARACTERISTICS : Age 18 80 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN No hepatic condition would interfere study medication Renal Creatinine clearance least 80 mL/min No renal condition would interfere study medication Cardiovascular No serious cardiac failure past year No myocardial infarction within past year No cardiac insufficiency No angina No uncontrolled arrhythmia No uncontrolled hypertension Gastrointestinal No superior intestinal tract malfunction No malabsorption syndrome Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection No serious illness No malignancy within past 5 year except curatively treat basal cell skin cancer carcinoma situ cervix No metabolic condition would interfere study medication No dementia alter mental status No psychiatric illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy colorectal cancer Endocrine therapy Not specify Radiotherapy No prior radiotherapy colorectal cancer Surgery Not specify Other More 30 day since prior participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>